Prescription opioids. VI. metabolism and excretion of hydromorphone in urine following controlled single-dose administration

Anne Z. DePriest, Rebecca Heltsley, David L. Black, John M. Mitchell, Charles LoDico, Ronald Flegel, Edward J. Cone

Research output: Contribution to journalArticle

Abstract

Hydromorphone (HM), a prescription opioid and metabolite of morphine and hydrocodone, has been included in proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This study characterized the time course of HM in hydrolyzed and non-hydrolyzed urine specimens. Twelve healthy subjects were administered a single 8 mg controlled-release HM dose, followed by periodic collection of pooled urine specimens for 54 h following administration. Analysis of total and free HM was conducted by liquid chromatography tandem mass spectrometry at a 50 ng/mL limit of quantitation. Detection periods were determined over a range of thresholds from 50 to 2,000 ng/mL. HM was detected in 85.3% and 47.6% of hydrolyzed and non-hydrolyzed post-dose specimens, respectively. Initial detection of total HM was frequently observed in the first 4-6 h following dosing. The period of detection at the 50 ng/mL threshold averaged 52.3 h for total HM and 38.0 h for free HM. These data support that HM detection is optimized by using low thresholds (50-100 ng/mL) and including conjugated HM in the analysis.

Original languageEnglish (US)
Article numberbkw066
Pages (from-to)575-582
Number of pages8
JournalJournal of Analytical Toxicology
Volume40
Issue number8
DOIs
StatePublished - Oct 1 2016

Fingerprint

Hydromorphone
Liquid chromatography
Metabolites
Metabolism
excretion
urine
Opioid Analgesics
Prescriptions
Mass spectrometry
metabolism
Urine
Testing
workplace
liquid chromatography
metabolite
drug
mass spectrometry
Hydrocodone
detection
dose

ASJC Scopus subject areas

  • Analytical Chemistry
  • Environmental Chemistry
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety

Cite this

DePriest, A. Z., Heltsley, R., Black, D. L., Mitchell, J. M., LoDico, C., Flegel, R., & Cone, E. J. (2016). Prescription opioids. VI. metabolism and excretion of hydromorphone in urine following controlled single-dose administration. Journal of Analytical Toxicology, 40(8), 575-582. [bkw066]. https://doi.org/10.1093/jat/bkw066

Prescription opioids. VI. metabolism and excretion of hydromorphone in urine following controlled single-dose administration. / DePriest, Anne Z.; Heltsley, Rebecca; Black, David L.; Mitchell, John M.; LoDico, Charles; Flegel, Ronald; Cone, Edward J.

In: Journal of Analytical Toxicology, Vol. 40, No. 8, bkw066, 01.10.2016, p. 575-582.

Research output: Contribution to journalArticle

DePriest, AZ, Heltsley, R, Black, DL, Mitchell, JM, LoDico, C, Flegel, R & Cone, EJ 2016, 'Prescription opioids. VI. metabolism and excretion of hydromorphone in urine following controlled single-dose administration', Journal of Analytical Toxicology, vol. 40, no. 8, bkw066, pp. 575-582. https://doi.org/10.1093/jat/bkw066
DePriest, Anne Z. ; Heltsley, Rebecca ; Black, David L. ; Mitchell, John M. ; LoDico, Charles ; Flegel, Ronald ; Cone, Edward J. / Prescription opioids. VI. metabolism and excretion of hydromorphone in urine following controlled single-dose administration. In: Journal of Analytical Toxicology. 2016 ; Vol. 40, No. 8. pp. 575-582.
@article{c6540e3971e742bba873b1b8a114b610,
title = "Prescription opioids. VI. metabolism and excretion of hydromorphone in urine following controlled single-dose administration",
abstract = "Hydromorphone (HM), a prescription opioid and metabolite of morphine and hydrocodone, has been included in proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This study characterized the time course of HM in hydrolyzed and non-hydrolyzed urine specimens. Twelve healthy subjects were administered a single 8 mg controlled-release HM dose, followed by periodic collection of pooled urine specimens for 54 h following administration. Analysis of total and free HM was conducted by liquid chromatography tandem mass spectrometry at a 50 ng/mL limit of quantitation. Detection periods were determined over a range of thresholds from 50 to 2,000 ng/mL. HM was detected in 85.3{\%} and 47.6{\%} of hydrolyzed and non-hydrolyzed post-dose specimens, respectively. Initial detection of total HM was frequently observed in the first 4-6 h following dosing. The period of detection at the 50 ng/mL threshold averaged 52.3 h for total HM and 38.0 h for free HM. These data support that HM detection is optimized by using low thresholds (50-100 ng/mL) and including conjugated HM in the analysis.",
author = "DePriest, {Anne Z.} and Rebecca Heltsley and Black, {David L.} and Mitchell, {John M.} and Charles LoDico and Ronald Flegel and Cone, {Edward J.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1093/jat/bkw066",
language = "English (US)",
volume = "40",
pages = "575--582",
journal = "Journal of Analytical Toxicology",
issn = "0146-4760",
publisher = "Preston Publications",
number = "8",

}

TY - JOUR

T1 - Prescription opioids. VI. metabolism and excretion of hydromorphone in urine following controlled single-dose administration

AU - DePriest, Anne Z.

AU - Heltsley, Rebecca

AU - Black, David L.

AU - Mitchell, John M.

AU - LoDico, Charles

AU - Flegel, Ronald

AU - Cone, Edward J.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Hydromorphone (HM), a prescription opioid and metabolite of morphine and hydrocodone, has been included in proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This study characterized the time course of HM in hydrolyzed and non-hydrolyzed urine specimens. Twelve healthy subjects were administered a single 8 mg controlled-release HM dose, followed by periodic collection of pooled urine specimens for 54 h following administration. Analysis of total and free HM was conducted by liquid chromatography tandem mass spectrometry at a 50 ng/mL limit of quantitation. Detection periods were determined over a range of thresholds from 50 to 2,000 ng/mL. HM was detected in 85.3% and 47.6% of hydrolyzed and non-hydrolyzed post-dose specimens, respectively. Initial detection of total HM was frequently observed in the first 4-6 h following dosing. The period of detection at the 50 ng/mL threshold averaged 52.3 h for total HM and 38.0 h for free HM. These data support that HM detection is optimized by using low thresholds (50-100 ng/mL) and including conjugated HM in the analysis.

AB - Hydromorphone (HM), a prescription opioid and metabolite of morphine and hydrocodone, has been included in proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This study characterized the time course of HM in hydrolyzed and non-hydrolyzed urine specimens. Twelve healthy subjects were administered a single 8 mg controlled-release HM dose, followed by periodic collection of pooled urine specimens for 54 h following administration. Analysis of total and free HM was conducted by liquid chromatography tandem mass spectrometry at a 50 ng/mL limit of quantitation. Detection periods were determined over a range of thresholds from 50 to 2,000 ng/mL. HM was detected in 85.3% and 47.6% of hydrolyzed and non-hydrolyzed post-dose specimens, respectively. Initial detection of total HM was frequently observed in the first 4-6 h following dosing. The period of detection at the 50 ng/mL threshold averaged 52.3 h for total HM and 38.0 h for free HM. These data support that HM detection is optimized by using low thresholds (50-100 ng/mL) and including conjugated HM in the analysis.

UR - http://www.scopus.com/inward/record.url?scp=84992168539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992168539&partnerID=8YFLogxK

U2 - 10.1093/jat/bkw066

DO - 10.1093/jat/bkw066

M3 - Article

VL - 40

SP - 575

EP - 582

JO - Journal of Analytical Toxicology

JF - Journal of Analytical Toxicology

SN - 0146-4760

IS - 8

M1 - bkw066

ER -